Analysis of the use of national health insurance negotiated drugs in Tianjin Second People's Hospital from 2018 to 2022
10.12173/j.issn.1008-049X.202310074
- VernacularTitle:2018-2022年天津市第二人民医院国家医保谈判药品使用情况分析
- Author:
Wenpeng FU
1
;
Defa ZHANG
;
Cheng LU
;
Jingsi WANG
Author Information
1. 天津市第二人民医院医保科(天津 300192)
- Keywords:
National health insurance negotiated drugs;
Medication frequency;
Average daily cost;
Health insurance
- From:
China Pharmacist
2024;27(2):317-324
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand the usage of national medical insurance negotiated drugs(hereinafter referred to as"negotiated drugs")at Tianjin Second People's Hospital and to provide references for optimizing and adjusting the hospital's drug catalog.Methods A retrospective study was conducted on the usage of negotiated drugs from January 1,2018 to December 31,2022 to compare changes in the unit price of drugs,the quantity and amount of sales,the usage frequency(DDDs)and the daily average cost(DDC),etc before and after the negotiation.Results Between 2018 and 2022,the varieties of negotiated drugs used in the hospital increased from the original 5 to 24.Among the 13 drugs analyzed for comparison,the unit prices of 11 drugs had been reduced after negotiation,and 7 drugs were included in the medical insurance and outpatient-specific disease payment directory.The average decrease in DDC was 36.43%,and the average increase in DDDs was 1 770.31%.The implementation of this policy had increased the accessibility of medication for patients and significantly increased sales quantity.Conclusion The quantity of sales of negotiated drugs significantly increased through reducing the unit price of drugs and including them in the scope of medical insurance payment,etc.These increase the pharmacoeconomic viability of negotiated drugs,effectively reduce the burden on patients,promote rational drug use in hospitals,and improve the access and efficiency of drugs.
